| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | SELL | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 3.34▲ | 3.41▲ | 3.41▲ | 3.46▼ | 3.31▲ |
| MA10 | 3.38▲ | 3.40▲ | 3.39▲ | 3.32▼ | 3.25▲ |
| MA20 | 3.33▲ | 3.32▲ | 3.31▲ | 3.32▼ | 2.95▲ |
| MA50 | 3.38▲ | 3.59▼ | 3.68▼ | 3.05▲ | N/A |
| MA100 | 3.85▼ | 3.56▼ | 3.27▲ | 2.86▲ | N/A |
| MA200 | 3.53▼ | 3.09▲ | 2.98▲ | N/A | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.013▲ | 0.033▲ | 0.032▲ | -0.005▼ | N/A |
| RSI | 55.129▲ | 52.042▲ | 51.794▲ | 50.320▲ | 49.710▼ |
| STOCH | 34.894 | 54.854 | 55.792 | 59.630 | 47.133 |
| WILL %R | -25.000 | -20.000▲ | -20.000▲ | -54.286 | -54.710 |
| CCI | 45.548 | 38.562 | 46.486 | 12.037 | 42.090 |
|
Wednesday, May 27, 2026 06:21 AM
Pre-IND meeting has been scheduled with FDA to advance type 1 diabetes treatment to First-In-Human clinical trial ZURICH, Switzerland, May 27, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (“NewcelX”; Nasdaq: ...
|
|
Monday, April 20, 2026 04:38 AM
ZURICH, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (Nasdaq: NCEL),– NewcelX Ltd. (Nasdaq: NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies ...
|
|
Tuesday, November 04, 2025 09:58 PM
View NewcelX Ltd. NCEL stock quote prices, financial information, real-time forecasts, and company news from CNN.
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 02/06/26 | 3.38 | 3.38 | 3.2401 | 3.32 | 9,601 |
| 01/06/26 | 3.46 | 3.48 | 3.31 | 3.48 | 18,603 |
| 29/05/26 | 3.57 | 3.57 | 3.4214 | 3.52 | 27,019 |
| 28/05/26 | 3.30 | 3.57 | 3.20 | 3.54 | 79,688 |
| 27/05/26 | 3.45 | 3.70 | 3.00 | 3.45 | 896,104 |
| 26/05/26 | 3.295 | 3.37 | 3.15 | 3.15 | 12,894 |
| 22/05/26 | 3.24 | 3.375 | 3.16 | 3.16 | 11,645 |
| 21/05/26 | 3.205 | 3.25 | 3.0392 | 3.18 | 2,565 |
| 20/05/26 | 3.24 | 3.31 | 3.10 | 3.25 | 4,858 |
| 19/05/26 | 3.03 | 3.18 | 3.00 | 3.18 | 3,943 |
|
|
||||
|
|
||||
|
|